|
||||||||||||||||||||||||
|
|
| Upcoming Programs | ||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||
Overview
Is hyperuricemia another door to the metabolic syndrome? This activity will focus on hyperuricemia and gout and will examine the latest guidance around treating patients in the primary care practice. The program will include a focus on the latest guidelines as well as applying the learning into everyday practice dynamics.
Objectives
List the key components of a differential diagnosis for gout based on clinical history and physical examination elements
Develop a treatment plan, which includes behavioral modification and pharmacologic strategies
Faculty
Robert Terkeltaub, MD
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
Overview
This presentation will address early and aggressive LDL-C management and the clinical challenges of goal attainment. Clinicians will be provided with pathways and knowledge to help them improve their patient outcomes by goal attainment of the healthy lipid profile.
Discussion will be applicable to clinicians' practice including lifestyle changes of diet and exercise, along with pharmacologic treatment options available for lipid management in order to give the appropriate tools to get patients to their true LDL goals.
Objectives
Understand the key tenets of assessing and managing dyslipidemia in clinical practice and the current evidence regarding the safety and efficacy of available LDL-C lowering therapies
Identify at least 2 lipid lowering strategies to initiate and tailor comprehensive management treatment plans for patients with high LDL-C in order to reach and maintain targeted goals
Faculty
Charles L. Campbell, MD
John Russell, MD
Clinical Associate Professor of Family and Community Medicine
Temple University School of Medicine
Philadelphia, PA
Overview
Leading clinicians will offer an interactive, case-based approach to the diagnosis and treatment of patients with pre-diabetes and diabetes to review the best methods to prevent disease onset and optimal treatment regimens to manage progression.
Objectives
Define pre-diabetes and monitor its development through the measurement of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)
Identify CVD risk factors in diabetic patients and be familiar with therapeutic goals and treatment strategies for dyslipidemia, hypertension, metabolic syndrome and obesity
Identify how ethnicity plays a role in CVD risk stratification
Identify strategies for the treatment of the diabetic patient with obesity including lifestyle changes, therapeutic strategies and surgical interventions
Devise a strategy for the use of insulin in the primary care practice, including short-acting and long-acting analogues, combination therapy and delivery devices
Describe incretin biology and current and emerging incretin therapeutics, including combination therapy, in the treatment of type 2 diabetes and explain the side effects of medication, which will improve patient compliance
Faculty
Tara Dall, MD
John Buse, MD, PhD
Professor of Medicine
Chief, Division of Endocrinology
Director of Diabetes Care Center
Executive Associate Dean for Clinical Research
University of North Carolina School of Medicine
Chapel Hill, NC
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
University of Pennsylvania Health System
Philadelphia, PA
Laurence Kennedy, MD, FRCP
Chair, Department of Endocrinology
Cleveland Clinic Foundation
Cleveland, OH
Overview
PAD is frequently unrecognized and many patients at risk are currently not identified and treated. Current estimates are that 8-12 million Americans have PAD, with the highest incidence among those over 70 years of age, regardless of health status, and people over 50 years of age with diabetes mellitus.
This lecture will overview the tremendous risk associated with PAD, discuss the major risk factors for developing PAD, and highlight the role of primary care in detecting and diagnosing the condition through increased use of ABI screening. Current therapies will be discussed including symptom improvement and prevention of future CV events with an emphasis on patient compliance issues.
Objectives
Identify the risk factors for those patients most at risk for PAD and therefore should be screened utilizing ABI.
Name the 2 goals of management of PAD
Faculty
Richard V. Milani, MD, FACC, FAHA
Vice-Chairman, Department of Cardiology
Ochsner Clinic Foundation
New Orleans, LA
Philip Altus, MD, MACP
Professor Emeritus, Department of Medicine
University of South Florida
Tampa, FL
Overview
Patients with refractory chronic low back pain represent a clinical challenge to primary care practitioners. Worsening persistent pain, an array of comorbid conditions, and loss of function coupled with a lack of evidence for treatment can create a clinical conundrum. Learn how to improve the longitudinal management of patients presenting to your practice with this ubiquitous and demanding condition.
Objectives
Select validated tools for use in comprehensive assessment and risk-stratification of patients with refractory chronic low back pain treated with opioids
Devise a treatment plan specific to the needs of chronic low back pain patients that demonstrate an understanding of recommended guidelines published jointly by the ACP/APS
Faculty
Zorba Paster, MD
Attending Physician, Family Practice
Department of Medicine
St. Marys Hospital
Madison, WI
Gerald M. Sacks, MD
Director of Pain Management
Saint John's Health Center
Santa Monica, CA
Overview
Insomnia, defined as complaints of disturbed sleep in the presence of adequate opportunity and circumstance for sleep, is the most common adult sleep pathology. Besides cognition, other pathologic processes have been deleteriously associated with insomnia, including cardiovascular morbidity and glycemic control. The latest evidence about sleep pathology will be presented, including spectral analysis that indicates sleep patterns, including slow wave sleep, are important, rather than just total sleep time. Nonpharmacologic approaches, as well as current and developing pharmacotherapies used to address these sleep pathologies will be described.
Objectives
Identify the underlying causes and comorbid conditions of insomnia for increased confidence in treatment
Assess the current and developing nonpharmacologic and pharmacologic approaches to the management of primary and comorbid insomnia
Faculty
David Neubauer, MD
Associate Professor
Department of Psychiatry
Johns Hopkins University School of Medicine
Associate Director
Johns Hopkins Sleep Disorders Center
Baltimore, MD
Paul P. Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services, Ursinus College
Collegeville, PA
Overview
Allergic rhinitis and chronic idiopathic urticaria, chronic histamine-induced conditions, negatively and significantly impact patient health and quality of life. However, current treatment options are only modestly successful, and obstacles remain to improving outcomes. Diagnostic Work-up and Management of Histamine-induced Disorders: Allergic Rhinitis and Chronic Urticaria will provide primary care clinicians with practical, evidence-based solutions for managing the challenges of these conditions, with an emphasis on finding effective treatments, managing side effects, and ensuring patient compliance.
Objectives
Identify strategies to overcome barriers for adequate control of allergic rhinitis symptoms
Create treatment strategies to improve outcomes for patients with chronic idiopathic urticaria
Faculty
Mark Corbett, MD
Michael S. Blaiss, MD
Clinical Professor of Pediatrics and Medicine
Division of Clinical Immunology and Allergy
University of Tennessee Health Science Center
Memphis, TN
Overview
Opioids provide effective pain management for acute and cancer pain and are useful in treating patients with chronic non-cancer pain who have not responded to other pain management therapies. Because of potential opioid abuse, patients and physicians may be reluctant to initiate opioid therapy for pain relief. This program will examine clinical strategies and recently published guidelines to balance effective opioid therapy against the risk of opioid misuse, abuse, and diversion.
Objectives
Differentiate the concepts of misuse, abuse, diversion, and addiction as defined in the APS/AAPM Clinical Guidelines for Opioid Therapy in Chronic Non-cancer Pain
Implement effective clinical strategies for managing opioid therapy in patients with acute and chronic non-cancer pain with consideration given to risk factors according to published guidelines
Faculty
Lynn Webster, MD
Medical Director
Lifetree Pain Clinic and Research Center
Chief of Anaesthesiology
Health South Salt Lake Surgery Center
Salt Lake City, UT